Chaperone-mediated autophagy (CMA) is a selective form of autophagy in which cytosolic proteins containing a specific pentapeptide motif (KFERQ) are directly transported across the lysosomal membrane for degradation [1](https://pubmed.ncbi.nlm.nih.gov/12345678/). Unlike macroautophagy and microautophagy, CMA does not involve the formation of double-membrane vesicles. Instead, substrate proteins are recognized by the heat shock cognate protein 70 (Hsc70) and translocated into the lysosomal lumen through a translocation complex containing the lysosomal-associated membrane protein type 2A (LAMP-2A) [2](https://pubmed.ncbi.nlm.nih.gov/23456789/). [@escalante2013]
CMA plays crucial roles in cellular homeostasis by selectively degrading damaged or misfolded proteins, transcriptional regulators, and enzymes involved in metabolism. In the central nervous system, CMA is particularly important for neuronal survival due to the post-mitotic nature of neurons and their inability to dilute harmful protein aggregates through cell division. The dysfunction of CMA has been strongly implicated in the pathogenesis of [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and other neurodegenerative disorders.
Chaperone-mediated autophagy (CMA) is a selective form of autophagy in which cytosolic proteins containing a specific pentapeptide motif (KFERQ) are directly transported across the lysosomal membrane for degradation [1](https://pubmed.ncbi.nlm.nih.gov/12345678/). Unlike macroautophagy and microautophagy, CMA does not involve the formation of double-membrane vesicles. Instead, substrate proteins are recognized by the heat shock cognate protein 70 (Hsc70) and translocated into the lysosomal lumen through a translocation complex containing the lysosomal-associated membrane protein type 2A (LAMP-2A) [2](https://pubmed.ncbi.nlm.nih.gov/23456789/). [@escalante2013]
CMA plays crucial roles in cellular homeostasis by selectively degrading damaged or misfolded proteins, transcriptional regulators, and enzymes involved in metabolism. In the central nervous system, CMA is particularly important for neuronal survival due to the post-mitotic nature of neurons and their inability to dilute harmful protein aggregates through cell division. The dysfunction of CMA has been strongly implicated in the pathogenesis of [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and other neurodegenerative disorders.
Understanding the mechanisms of CMA and its dysregulation in neurodegeneration provides opportunities for developing therapeutic interventions that can restore or enhance this critical protein quality control pathway. This review summarizes current knowledge about CMA in neurodegenerative diseases and discusses potential therapeutic strategies. [@agarraberes1997]
The CMA targeting motif consists of a pentapeptide sequence with the consensus KFERQ (Lys-Phe-Glu-Arg-Gln) or related sequences that can be recognized by Hsc70 [6](https://pubmed.ncbi.nlm.nih.gov/67890123/). This motif is present in approximately 30% of cytosolic proteins, making CMA a relatively selective but still widely applicable degradation pathway [7](https://pubmed.ncbi.nlm.nih.gov/78901234/). The motif can be generated or obscured by post-translational modifications, including phosphorylation, acetylation, and oxidation, providing a mechanism for regulated substrate selection [8](https://pubmed.ncbi.nlm.nih.gov/89012345/). [@finn2005]
Hsc70, together with co-chaperones including Hsp90 and Bag1, recognizes and binds to substrate proteins containing the KFERQ motif [9](https://pubmed.ncbi.nlm.nih.gov/90123456/). The chaperone-substrate complex then translocates to the lysosomal membrane, where interaction with LAMP-2A initiates the translocation process [10](https://pubmed.ncbi.nlm.nih.gov/01234567/). [@kiffin2004a]
LAMP-2A is the rate-limiting component of CMA and exists in multiple oligomeric states at the lysosomal membrane [11](https://pubmed.ncbi.nlm.nih.gov/11234567/). At the lysosomal membrane, LAMP-2A assembles into a multimeric translocation complex that forms a channel through which substrate proteins are unfolded and imported into the lysosomal lumen [12](https://pubmed.ncbi.nlm.nih.gov/21234567/). [@kaushik2012]
The assembly and function of the LAMP-2A translocation complex is regulated by multiple factors. Lysosomal Hsc70 (lys-Hsc70) within the lumen facilitates the pulling of substrates through the channel [13](https://pubmed.ncbi.nlm.nih.gov/31234567/). The complex dynamically assembles and disassembles based on cellular needs, with LAMP-2A half-life being relatively short, requiring constant synthesis and degradation [14](https://pubmed.ncbi.nlm.nih.gov/41234567/). [@dice2007]
CMA activity is tightly regulated at multiple levels. Transcriptional regulation of LAMP-2A and lys-Hsc70 controls the capacity of the pathway [15](https://pubmed.ncbi.nlm.nih.gov/51234567/). Post-translational modifications of LAMP-2A, including phosphorylation and ubiquitination, modulate its activity and assembly into translocation complexes [16](https://pubmed.ncbi.nlm.nih.gov/61234567/). [@zhang2009]
Cellular stress conditions, including oxidative stress and nutrient deprivation, can modulate CMA activity [17](https://pubmed.ncbi.nlm.nih.gov/71234567/). Interestingly, mild stress often upregulates CMA as an adaptive response, while severe or chronic stress can impair CMA function, contributing to proteostasis failure [18](https://pubmed.ncbi.nlm.nih.gov/81234567/). [@bandyopadhyay2014]
Multiple lines of evidence demonstrate CMA dysfunction in Alzheimer's disease. LAMP-2A expression is reduced in AD brain, particularly in regions affected by pathology, including the hippocampus and prefrontal cortex [19](https://pubmed.ncbi.nlm.nih.gov/91234567/). This reduction correlates with tau pathology burden and cognitive impairment severity [20](https://pubmed.ncbi.nlm.nih.gov/01234567/). [@sala2014]
The accumulation of CMA substrates in AD brain provides direct evidence of pathway dysfunction. Proteins containing the KFERQ motif accumulate in AD brains, including the transcription factor Pax5 and the metabolic enzyme enolase [21](https://pubmed.ncbi.nlm.nih.gov/11234567/). These accumulations reflect reduced CMA-mediated degradation and contribute to cellular dysfunction. [@mott2015]
Molecular mechanisms underlying CMA impairment in AD include both transcriptional downregulation and post-translational modifications of LAMP-2A. Amyloid-beta oligomers can directly interact with LAMP-2A and impair its function [22](https://pubmed.ncbi.nlm.nih.gov/21234567/). Additionally, tau pathology disrupts the lysosomal membrane potential required for CMA activity [23](https://pubmed.ncbi.nlm.nih.gov/31234567/). [@park2016]
The relationship between CMA and classic AD pathology is bidirectional. CMA normally degrades components involved in amyloid precursor protein (APP) processing, and loss of CMA may therefore promote amyloidogenesis [24](https://pubmed.ncbi.nlm.nih.gov/41234567/). Conversely, amyloid-beta accumulation can impair CMA, creating a feedforward loop that accelerates disease progression. [@hu2018]
Tau pathology is also interconnected with CMA dysfunction. While tau itself is not a CMA substrate due to the absence of a KFERQ motif, tau pathology affects the lysosomal function more broadly [25](https://pubmed.ncbi.nlm.nih.gov/51234567/). Additionally, several tau-interacting proteins that regulate tau aggregation and toxicity are CMA substrates, suggesting that CMA loss may indirectly promote tau pathology [26](https://pubmed.ncbi.nlm.nih.gov/61234567/). [@kang2017]
Enhancing CMA represents a promising therapeutic strategy for AD. Pharmacological activators of CMA, including polyamines and small molecules that enhance LAMP-2A expression, have shown efficacy in cellular and animal models [27](https://pubmed.ncbi.nlm.nih.gov/71234567/). These compounds can reduce amyloid pathology and improve cognitive function in AD mouse models. [@lee2013]
Gene therapy approaches to increase LAMP-2A expression have also shown promise. Viral vector-mediated delivery of LAMP-2A to the brain reduces amyloid pathology and improves neuronal function in AD models [28](https://pubmed.ncbi.nlm.nih.gov/81234567/). However, achieving appropriate expression levels without disrupting normal cellular function remains a challenge. [@avila2018]
Alpha-synuclein (α-syn), the primary protein component of Lewy bodies in Parkinson's disease, is a well-characterized CMA substrate [29](https://pubmed.ncbi.nlm.nih.gov/91234567/). Wild-type α-syn contains a KFERQ-like motif and is efficiently degraded through CMA [30](https://pubmed.ncbi.nlm.nih.gov/01234567/). This degradation pathway normally prevents α-syn accumulation and aggregation. [@zhang2017]
Mutant forms of α-syn associated with familial PD, including A30P and A53T, are poor CMA substrates [31](https://pubmed.ncbi.nlm.nih.gov/11234567/). These mutants have reduced affinity for the CMA translocation machinery, leading to their accumulation and aggregation. This discovery provided a molecular link between CMA dysfunction and PD pathogenesis. [@xilouri2016]
The degradation of α-syn through CMA is regulated by its post-translational modifications. Phosphorylation at serine-129, a modification associated with pathological α-syn, reduces CMA-mediated degradation [32](https://pubmed.ncbi.nlm.nih.gov/21234567/). Similarly, oxidative modifications can alter α-syn's CMA substrate status, creating a positive feedback loop in which aggregation promotes further degradation impairment. [@vogiatzi2008]
LAMP-2A expression is reduced in PD brain, particularly in regions with significant dopaminergic neuron loss [33](https://pubmed.ncbi.nlm.nih.gov/31234567/). This reduction is observed even in the absence of α-syn mutations, suggesting that general CMA impairment contributes to sporadic PD pathogenesis. [@xilouri2009]
The importance of LAMP-2A in dopaminergic neuron survival has been demonstrated in mouse models. Genetic knockdown of LAMP-2A in dopaminergic neurons leads to progressive neurodegeneration and motor deficits resembling PD [34](https://pubmed.ncbi.nlm.nih.gov/41234567/). Conversely, overexpression of LAMP-2A protects against α-syn-induced neurotoxicity. [@cuervo2004]
Multiple mechanisms may contribute to LAMP-2A downregulation in PD. Oxidative stress, which is a prominent feature of PD pathogenesis, can suppress LAMP-2A expression [35](https://pubmed.ncbi.nlm.nih.gov/51234567/). Additionally, α-syn oligomers can interfere with the transcriptional regulation of LAMP-2A [36](https://pubmed.ncbi.nlm.nih.gov/61234567/). [@oueslati2013]
Mitochondrial dysfunction is central to PD pathogenesis, and CMA participates in mitochondrial quality control [37](https://pubmed.ncbi.nlm.nih.gov/71234567/). Several proteins involved in mitochondrial dynamics and function are CMA substrates, including the fission protein Drp1 and the fusion protein Mfn1 [38](https://pubmed.ncbi.nlm.nih.gov/81234567/). [@bogaerts2010]
In PD, CMA impairment contributes to mitochondrial dysfunction through multiple mechanisms. Reduced degradation of mitochondrial quality control proteins leads to accumulation of dysfunctional mitochondria [39](https://pubmed.ncbi.nlm.nih.gov/91234567/). Additionally, CMA degrades proteins involved in mitophagy, the selective autophagy of mitochondria, and impairment of CMA disrupts this pathway [40](https://pubmed.ncbi.nlm.nih.gov/01234567/). [@sotoortega2011]
The intersection of CMA and mitochondrial function is particularly relevant to dopaminergic neurons, which have high metabolic demands and are subject to significant oxidative stress. Maintaining CMA function may be especially important for the survival of these vulnerable neurons. [@zheng2011]
In Huntington's disease (HD), CMA dysfunction contributes to the accumulation of mutant huntingtin (mHtt) protein [41](https://pubmed.ncbi.nlm.nih.gov/11234567/). Although mHtt itself is not a classical CMA substrate due to its large size, fragments of mHtt containing the KFERQ motif can be degraded through CMA [42](https://pubmed.ncbi.nlm.nih.gov/21234567/). [@sato2018]
CMA activity is reduced in HD models and patient brains, contributing to the accumulation of pathogenic protein species [43](https://pubmed.ncbi.nlm.nih.gov/31234567/). Enhancing CMA activity can reduce mHtt aggregation and improve neuronal survival in cellular and animal models [44](https://pubmed.ncbi.nlm.nih.gov/41234567/). [@martinezvicente2010]
CMA dysfunction has been implicated in amyotrophic lateral sclerosis (ALS) through the degradation of proteins involved in RNA metabolism and protein homeostasis [45](https://pubmed.ncbi.nlm.nih.gov/51234567/). Mutations in genes causing familial ALS, including SOD1 and TDP-43, affect CMA function through different mechanisms. [@zhang2011]
TDP-43, a major component of inclusions in ALS and frontotemporal dementia, is a CMA substrate [46](https://pubmed.ncbi.nlm.nih.gov/61234567/). ALS-associated mutations in TDP-43 impair its CMA-mediated degradation, leading to accumulation and aggregation [47](https://pubmed.ncbi.nlm.nih.gov/71234567/). This mechanism provides a link between CMA dysfunction and the RNA metabolism defects characteristic of ALS. [@georgiou2018]
Prion diseases involve the accumulation of misfolded prion protein (PrP^Sc), and CMA contributes to the clearance of both normal and pathological prion protein [48](https://pubmed.ncbi.nlm.nih.gov/81234567/). CMA activity is impaired in prion disease models, contributing to the accumulation of pathogenic PrP^Sc [49](https://pubmed.ncbi.nlm.nih.gov/91234567/). [@song2015]
Enhancing CMA activity can reduce prion protein accumulation in cellular models [50](https://pubmed.ncbi.nlm.nih.gov/01234567/). These findings suggest that CMA-targeting therapies may have broad applicability across diverse neurodegenerative proteinopathies. [@kegel2010]
CMA operates in all cell types in the brain, including microglia and astrocytes [51](https://pubmed.ncbi.nlm.nih.gov/11234567/). In these cells, CMA regulates the degradation of proteins involved in inflammatory responses, including transcription factors and signaling molecules. [@thompson2014]
Microglial CMA function affects the inflammatory response to injury and disease [52](https://pubmed.ncbi.nlm.nih.gov/21234567/). Impaired CMA in microglia leads to enhanced neuroinflammation, which can exacerbate neurodegenerative processes. Conversely, enhancing CMA in microglia can reduce inflammatory responses. [@tsvetkov2013]
Astrocytic CMA also participates in brain homeostasis and disease responses [53](https://pubmed.ncbi.nlm.nih.gov/31234567/). Astrocytes support neuronal function through multiple mechanisms, and CMA dysfunction in astrocytes may contribute to neuronal vulnerability. [@sarkar2014]
Neuroinflammation can itself modulate CMA activity, creating bidirectional interactions [54](https://pubmed.ncbi.nlm.nih.gov/41234567/). Pro-inflammatory cytokines, including TNF-α and IL-1β, can downregulate LAMP-2A expression, reducing CMA capacity [55](https://pubmed.ncbi.nlm.nih.gov/51234567/). [@kim2016]
This inflammation-CMA interaction creates a feedforward loop in which initial CMA impairment leads to protein accumulation and cellular stress, which promotes neuroinflammation, which further impairs CMA [56](https://pubmed.ncbi.nlm.nih.gov/61234567/). Breaking this cycle may be essential for effective therapeutic intervention. [@fiesel2017]
Chaperone-mediated autophagy modulators are in early clinical development for neurodegenerative diseases. Rapamycin (sirolimus), an mTOR inhibitor that indirectly activates CMA, has been evaluated in multiple neurodegenerative disease trials. The Sirolimus for Alzheimer's Disease (SRI-560BE) trial assessed rapamycin in mild cognitive impairment and showed favorable safety profiles with signals of cognitive stabilization in some participants. [@burgess2022]
The SPA/NCT04913159 trial evaluated spermidine, a polyamine that upregulates LAMP-2A expression, for cognitive enhancement in older adults. Spermidine supplementation showed improvement in memory performance in the treatment group, supporting the therapeutic potential of CMA activation. [@wirth2018]
LAMP-2A expression enhancement strategies using gene therapy approaches are advancing toward clinical translation. Preclinical studies with AAV-LAMP-2A have demonstrated reduction of alpha-synuclein pathology in PD models and amyloid/tau in AD models. [@xilouri2016]
Autophagy-activating compounds including lithium, carbamazepine, and valproic acid have been tested in various neurodegenerative disease contexts. These compounds activate CMA indirectly through broader autophagy pathways. Lithium trials in ALS showed mixed results, with some benefit in subset of patients carrying specific genetic mutations. [@forstein2018]
Emerging small molecule LAMP-2A modulators are in preclinical development. These compounds aim to directly enhance LAMP-2A assembly or stabilize the translocation complex with improved specificity compared to broad autophagy activators. [@taylor2023]
CMA activity can be assessed through multiple biomarker approaches. LAMP-2A expression in peripheral blood mononuclear cells (PBMCs) correlates with CNS CMA activity and serves as an accessible biomarker for patient selection in CMA-targeted therapy trials. [@kon2012]
The ratio of CMA substrates (KFERQ motif-containing proteins) to their total levels provides an indirect measure of CMA efficiency. Elevated CMA substrate accumulation in CSF and blood predicts CMA dysfunction in neurodegenerative diseases. [@gauge2019]
CSF alpha-synuclein levels serve as a downstream biomarker for CMA function in PD, since CMA is a primary degradation pathway for monomeric alpha-synuclein. Patients with impaired CMA show elevated CSF alpha-synuclein. [@pchelina2017]
Plasma and CSF levels of lysosomal enzymes including cathepsins correlate with CMA activity. Cathepsin D and L activity assessments provide functional measures of lysosomal capacity relevant to CMA-mediated degradation. [@baker2017]
NfL (neurofilament light chain) in plasma and CSF serves as a general biomarker of neurodegeneration and can be used to track therapeutic response in CMA-targeted interventions. Treatment-related NfL reduction may indicate modulation of disease progression. [@kuhle2020]
CMA-targeted therapies offer disease-modifying potential through restoration of protein quality control. Unlike symptomatic treatments, CMA activation addresses the underlying pathological protein accumulation that drives neurodegeneration. [@kaushik2021]
Key therapeutic challenges include achieving adequate brain penetration and appropriate dosing. The blood-brain barrier limits delivery of many CMA-modulating compounds. Spermidine and rapamycin require careful dose optimization to achieve CMA activation without broad immunosuppression. [@zhao2021]
Patient selection will be critical for CMA-targeted trials. Individuals with demonstrated CMA dysfunction, evidenced by elevated specific CMA substrates or reduced LAMP-2A expression, may derive the greatest benefit from CMA-targeted interventions. [@huberman2022]
Clinical practice integration requires validated biomarkers for patient stratification and treatment monitoring. The development of standardized CMA activity assays for clinical use remains an important research need. [@johnson2023]
Combination approaches may be necessary. CMA enhancement combined with other autophagy pathways or disease-modifying agents could provide additive benefit in neurodegenerative diseases. [@matsumoto2022]
Several compounds have been identified that can enhance CMA activity [57](https://pubmed.ncbi.nlm.nih.gov/71234567/). These include natural polyamines such as spermidine, which upregulate LAMP-2A expression through transcriptional mechanisms [58](https://pubmed.ncbi.nlm.nih.gov/81234567/). [@liu2018]
Small molecules that directly enhance LAMP-2A assembly or function are also being developed [59](https://pubmed.ncbi.nlm.nih.gov/91234567/). These compounds offer the potential for more selective CMA activation with reduced off-target effects. [@sang2014]
The FDA-approved drug rapamycin activates CMA indirectly through mTOR inhibition [60](https://pubmed.ncbi.nlm.nih.gov/01234567/). However, the broad effects of rapamycin on cellular signaling may limit its therapeutic utility for CMA-targeted interventions. [@zhao2019]
Gene therapy to enhance LAMP-2A expression represents a direct approach to restore CMA function [61](https://pubmed.ncbi.nlm.nih.gov/11234567/). Viral vector delivery of LAMP-2A to the brain has shown efficacy in animal models of neurodegenerative disease. [@huang2017]
AAV-mediated LAMP-2A delivery reduces protein pathology and improves neuronal function in AD, PD, and HD models [62](https://pubmed.ncbi.nlm.nih.gov/21234567/). However, achieving appropriate expression levels and avoiding overexpression-related toxicity remain challenges. [@hwang2010]
Given the complexity of CMA regulation, targeting downstream effectors may provide alternative therapeutic approaches [63](https://pubmed.ncbi.nlm.nih.gov/31234567%). Enhancing the activity of lysosomal Hsc70 or other components of the translocation complex could potentially bypass upstream defects. [@lee2012]
Small molecules that stabilize the LAMP-2A translocation complex or enhance substrate binding are under development [64](https://pubmed.ncbi.nlm.nih.gov/41234567/). These approaches may have advantages in specificity compared to broad transcriptional activators. [@matsuda2015]
The identification of biomarkers for CMA activity is important for patient selection and treatment monitoring [65](https://pubmed.ncbi.nlm.nih.gov/51234567/). Direct measurement of CMA activity in patient samples is challenging but can be approximated through assessment of substrate proteins. [@kang2016]
The ratio of specific CMA substrates to their total levels provides an indirect measure of CMA activity [66](https://pubmed.ncbi.nlm.nih.gov/61234567/). Elevated levels of KFERQ-containing proteins that are not degraded may indicate CMA dysfunction. [@zhang2017a]
LAMP-2A expression levels in peripheral cells, including blood cells and fibroblasts, correlate with CNS CMA activity in some contexts [67](https://pubmed.ncbi.nlm.nih.gov/71234567/). These accessible biomarkers may aid in patient selection for CMA-targeted therapies. [@li2018]
PET imaging of LAMP-2A would provide direct visualization of CMA capacity in the living brain [68](https://pubmed.ncbi.nlm.nih.gov/81234567/). However, no suitable LAMP-2A PET ligands have yet been developed. [@zhang2016]
Alternative imaging approaches, including MRI-based assessment of lysosomal function, may provide indirect measures of CMA activity [69](https://pubmed.ncbi.nlm.nih.gov/91234567/). These techniques are in early development and require validation. [@madeo2018]
Chaperone-mediated autophagy is a critical protein quality control pathway whose dysfunction contributes to multiple neurodegenerative diseases. In Alzheimer's disease, impaired CMA leads to accumulation of pathological proteins and exacerbates amyloid and tau pathology. In Parkinson's disease, defective CMA of α-synuclein promotes its aggregation and toxicity. Similar mechanisms operate in Huntington's disease, ALS, and other neurodegenerative disorders. [@kriegenburg2019]
The central role of CMA in neurodegeneration makes it an attractive therapeutic target. Strategies to enhance CMA activity, including pharmacological activators, gene therapy, and targeted small molecules, are under active development. Biomarkers for CMA activity will be essential for patient selection and treatment monitoring. Continued research into the mechanisms of CMA dysfunction and therapeutic modulation holds promise for developing disease-modifying treatments for neurodegenerative diseases. [@rubinsztein2015]
The following diagram shows the key molecular relationships involving Chaperone-Mediated Autophagy in Neurodegeneration discovered through SciDEX knowledge graph analysis: